查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1995852

人工智慧（AI）在临床试验中的市场：策略性洞察与预测（2026-2031 年）

Artificial Intelligence (AI) in Clinical Trials Market - Strategic Insights and Forecasts (2026-2031)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球临床试验人工智慧 (AI) 市场预计将从 2026 年的 76 亿美元成长到 2031 年的 469 亿美元，复合年增长率为 43.92%。

人工智慧（AI）在临床试验领域的应用正日益成为优化现代药物研发和临床研究的关键要素。製药公司、生物技术公司和研究机构正越来越多地采用人工智慧技术来解决传统临床试验流程中的效率低下问题。传统的临床试验耗费资源、时间长，且失败率高。人工智慧提供先进的数据分析、预测建模和自动化功能，能够有效改善试验设计、受试者招募和监测流程。

全球对加速药物研发的需求日益增长，尤其是在罕见疾病和遗传疾病领域，这正在塑造这个市场。医疗保健数据的日益丰富以及精准医疗的需求，正在加速人工智慧驱动的临床研究工具的应用。人工智慧技术使製药公司能够分析大量资料集，增强受试者的多样性，并在整个试验週期中强化决策。随着研发流程日益复杂，成本压力不断增加，人工智慧解决方案在提高效率、降低营运风险和提升临床试验成功率方面正发挥越来越重要的策略作用。

市场驱动因素

成长要素之一是对高效药物发现和开发日益增长的需求。製药公司正在利用人工智慧简化临床实验计划、降低成本并缩短产品上市时间。人工智慧能够实现更快的数据处理、预测分析和即时监测，有助于改善临床实验结果并降低营运复杂性。

对罕见疾病和遗传疾病的研究不断深入，也推动了对人工智慧的需求。人工智慧有助于识别合适的患者群体、改进生物标记分析并优化通讯协定。这些能力在传统方法效率低下的复杂治疗领域中尤其重要。

另一个关键驱动因素是製药公司和研究机构对人工智慧的日益重视。领先的製药公司正透过与人工智慧技术供应商合作或建立内部研发能力，加强临床试验的设计和执行。全球临床试验数量的成长也催生了扩充性分析工具的需求，进一步推动了市场成长。

市场限制因素

儘管预计市场将保持强劲成长，但仍面临许多营运和结构性挑战。人工智慧在临床研究中的应用需要复杂的资料基础设施、熟练的专业人员以及完善的监管合规框架。这些要求会增加实施的复杂性和成本。

数据品质和标准化也是挑战。临床试验数据来自多个来源，包括电子健康记录、穿戴式装置和监测系统。确保资料集之间的互通性和准确性十分困难，这可能会限制人工智慧在某些应用中的效能。

此外，法规和伦理考量也限制科技的应用。临床研究需要严格遵守安全和隐私标准，这可能会延缓新技术的引入，并延长核准时间。

对技术和细分市场的洞察

该市场涵盖多个基于流程的应用，包括试验设计、受试者选择、研究中心选择和受试者监测。人工智慧工具贯穿整个临床开发生命週期，从通讯协定製定到试验后分析。

应用领域包括生物感测器、智慧型手机应用程式和穿戴式技术。这些解决方案能够实现即时数据采集、远端监测和持续的病人参与。这些功能支持分散式和混合式临床试验模式，从而提高数据品质和患者参与率。

人工智慧技术正日益广泛地应用于数据分析自动化、优化受试者招募策略以及提高结果预测的准确性。机器学习演算法支援模式识别和预测建模，使研究人员能够及早发现风险并优化试验设计。

从区域上看，北美占据了很大的份额，因为其医疗保健支出高、研究基础设施先进，并且积极采用数位健康技术。

竞争格局与策略展望

竞争格局包括人工智慧临床研究专家和技术供应商，他们提供分析平台、资料管理解决方案和试验优化工具。製药公司与人工智慧开发商之间的策略合作是该市场的显着特征。

各公司正致力于在整个临床开发流程中扩展人工智慧能力，包括预测性试验设计、自动化监测和数位化病人参与。随着各机构努力提高试验效率及降低开发风险，研发投入依然强劲。

重点

人工智慧正在透过提高效率、降低成本和增强数据驱动决策来变革临床试验运作。随着製药业创新加速和试验复杂性增加，人工智慧的应用预计将显着扩展。儘管监管和数据整合的挑战依然存在，但人工智慧驱动的临床研究的长期前景仍然十分光明。

本报告的主要益处

  • 深入分析：获得跨地区、客户群、政策、社会经济因素、消费者偏好和产业领域的详细市场洞察。
  • 竞争格局：了解主要企业的策略趋势，并确定最佳的市场进入方式。
  • 市场驱动因素和未来趋势：我们将评估影响市场的关键成长要素和新兴趋势。
  • 实用建议：我们支援制定策略决策以开发新的收入来源。
  • 适合各类读者：非常适合Start-Ups、研究机构、顾问公司、中小企业和大型企业。

我们的报告的使用范例

产业和市场洞察、机会评估、产品需求预测、打入市场策略、区域扩张、资本投资决策、监管分析、新产品开发和竞争情报。

报告范围

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率评估
  • 细分市场和区域销售成长及预测评估
  • 公司简介，包括策略、产品、财务状况和主要发展动态。

目录

第一章：引言

  • 市场概览
  • 市场的定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年及预测年调查期

第二章：调查方法

  • 调查数据
  • 调查设计

第三章执行摘要

  • 调查要点

第四章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章：临床试验中的人工智慧（AI）市场：依流程划分

  • 测试设计
  • 选题
  • 临床实验中心选择
  • 病患监测

第六章：人工智慧（AI）在临床试验中的市场：按应用领域划分

  • 生物感测器
  • 智慧型手机应用程式
  • 穿戴式装置

第七章：人工智慧（AI）在临床试验中的市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • UAE
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 越南
    • 其他的

第八章：竞争环境与分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作关係
  • 市占率分析

第九章：公司简介

  • ConcertAI
  • Saama Technologies LLC
  • PathAI
  • Owkin Inc.
  • Aitia
  • Neuroute
  • AiCure
  • Unlearn AI
  • VeriSIM Life
简介目录
Product Code: KSI061614838

The Global Artificial Intelligence (AI) in Clinical Trials market is forecast to grow at a CAGR of 43.92%, reaching USD 46.9 billion in 2031 from USD 7.6 billion in 2026.

The artificial intelligence in clinical trials market is emerging as a critical component of modern drug development and clinical research optimization. Pharmaceutical companies, biotechnology firms, and research organizations are increasingly adopting AI technologies to address inefficiencies in traditional clinical trial processes. Clinical trials have historically been resource intensive, time consuming, and subject to high failure rates. Artificial intelligence offers advanced data analytics, predictive modeling, and automation capabilities that enhance trial design, patient recruitment, and monitoring processes.

The market is being shaped by growing global demand for faster drug development, particularly for rare and genetic diseases. Increasing healthcare data availability and the need for precision medicine are accelerating adoption of AI driven clinical research tools. AI technologies enable pharmaceutical companies to analyze large datasets, improve trial population diversity, and enhance decision making throughout the trial lifecycle. As research pipelines become more complex and cost pressures intensify, AI solutions are gaining strategic importance in improving efficiency, reducing operational risks, and increasing success probabilities in clinical trials.

Market Drivers

One of the key growth drivers is the rising need for efficient drug discovery and development. Pharmaceutical firms are leveraging AI to streamline trial planning, reduce costs, and accelerate time to market. AI enables faster data processing, predictive analytics, and real time monitoring, which help improve trial outcomes and reduce operational complexity.

Growing research into rare and genetic diseases is also driving demand. AI supports the identification of suitable patient populations, improves biomarker analysis, and enhances protocol optimization. These capabilities are particularly valuable in complex therapeutic areas where conventional methods may be inefficient.

Another important driver is increasing adoption by pharmaceutical companies and research organizations. Major drug manufacturers are collaborating with AI technology providers or developing in house capabilities to enhance clinical trial design and execution. The expanding number of clinical trials globally further supports market growth by creating demand for scalable analytical tools.

Market Restraints

Despite strong growth prospects, the market faces several operational and structural challenges. Integration of AI into clinical research requires advanced data infrastructure, skilled personnel, and regulatory compliance frameworks. These requirements can increase implementation complexity and cost.

Data quality and standardization also present challenges. Clinical trial data originates from multiple sources, including electronic health records, wearable devices, and monitoring systems. Ensuring interoperability and accuracy across datasets can be difficult and may limit AI performance in certain applications.

Regulatory and ethical considerations further constrain adoption. Clinical research requires strict compliance with safety and privacy standards, which can slow deployment of new technologies and increase approval timelines.

Technology and Segment Insights

The market spans several process based applications, including trial design, patient selection, site selection, and patient monitoring. AI tools are integrated across the full clinical development lifecycle, from protocol development to post trial analysis.

Application segments include biosensors, smartphone applications, and wearable technologies. These solutions enable real time data collection, remote monitoring, and continuous patient engagement. Such capabilities support decentralized and hybrid clinical trial models, improving data quality and patient participation.

AI technologies are increasingly used to automate data analysis, enhance recruitment strategies, and improve outcome prediction. Machine learning algorithms support pattern recognition and predictive modeling, enabling researchers to identify risks earlier and optimize study design.

Regionally, North America holds a significant share due to high healthcare expenditure, advanced research infrastructure, and strong adoption of digital health technologies.

Competitive and Strategic Outlook

The competitive landscape includes specialized AI clinical research firms and technology providers offering analytics platforms, data management solutions, and trial optimization tools. Strategic partnerships between pharmaceutical companies and AI developers are a defining feature of the market.

Companies are focusing on expanding AI capabilities across clinical development workflows, including predictive trial design, automated monitoring, and digital patient engagement. Investment in research and innovation remains strong as organizations seek to improve trial efficiency and reduce development risk.

Key Takeaways

Artificial intelligence is reshaping clinical trial operations by improving efficiency, reducing costs, and enhancing data driven decision making. As pharmaceutical innovation accelerates and trial complexity increases, AI adoption is expected to expand significantly. While regulatory and data integration challenges remain, the long term outlook for AI enabled clinical research remains highly positive.

Key Benefits of this Report

  • Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What businesses use our reports for

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2025 and forecast data from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. AI IN CLINICAL TRIALS MARKET BY PROCESS

  • 5.1. Introduction
  • 5.2. Trial Design
  • 5.3. Patient Selection
  • 5.4. Site Selection
  • 5.5. Patient Monitoring

6. AI IN CLINICAL TRIALS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Biosensors
  • 6.3. Smartphone Applications
  • 6.4. Wearables

7. AI IN CLINICAL TRIALS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Australia
    • 7.6.6. Indonesia
    • 7.6.7. Vietnam
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Market Share Analysis

9. COMPANY PROFILES

  • 9.1. ConcertAI
  • 9.2. Saama Technologies LLC
  • 9.3. PathAI
  • 9.4. Owkin Inc.
  • 9.5. Aitia
  • 9.6. Neuroute
  • 9.7. AiCure
  • 9.8. Unlearn AI
  • 9.9. VeriSIM Life